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Abstract
The continued emergence and spread of infectious agents is of great concern, and systems biology 
approaches to infectious disease research can advance our understanding of host-pathogen 
relationships and facilitate the development of new therapies and vaccines. Molecular 
characterization of infectious samples outside of appropriate biosafety containment can take place 
only subsequent to pathogen inactivation. Herein, we describe a modified Folch extraction using 
chloroform/methanol that facilitates the molecular characterization of infectious samples by 
enabling simultaneous pathogen inactivation and extraction of proteins, metabolites, and lipids for 
subsequent mass spectrometry-based multi-omics measurements. This single-sample metabolite, 
protein and lipid extraction (MPLEx) method resulted in complete inactivation of clinically 
important bacterial and viral pathogens with exposed lipid membranes, including Yersinia pestis, 
Salmonella Typhimurium, and Campylobacter jejuni in pure culture, and Yersinia pestis, 
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Campylobacter jejuni, and West Nile, MERS-CoV, Ebola, and influenza H7N9 viruses in infection 
studies. In addition, >99% inactivation, which increased with solvent exposure time, was also 
observed for pathogens without exposed lipid membranes including community-associated 
methicillin-resistant Staphylococcus aureus, Clostridium difficile spores and vegetative cells, and 
adenovirus type 5. The overall pipeline of inactivation and subsequent proteomic, metabolomic, 
and lipidomic analyses was evaluated using a human epithelial lung cell line infected with wild-
type and mutant influenza H7N9 viruses, thereby demonstrating that MPLEx yields biomaterial of 
sufficient quality for subsequent multi-omics analyses. Based on these experimental results, we 
believe that MPLEx will facilitate systems biology studies of infectious samples by enabling 
simultaneous pathogen inactivation and multi-omics measurements from a single specimen with 
high success for pathogens with exposed lipid membranes.
Infectious disease research is of global interest since the emergence and spread of infectious 
agents represent ongoing challenges due to population growth and associated increased 
livestock production to meet food demands, increased urbanization and land-use changes, 
and greater travel1–5. Emerging infectious diseases are often zoonotic and can be transmitted 
to humans from animals (e.g., Middle Eastern Respiratory Syndrome coronavirus (MERS-
CoV); West Nile virus, influenza A viruses, and Ebola)3. As recently demonstrated by the 
2014 Ebola virus infection diagnoses in the United States, the ease of world travel and 
increased global interdependence have added complexity to containing these infectious 
diseases6. Similarly, as new infectious diseases evolve and emerge, preexisting infectious 
diseases re-emerge with new genetic adaptations. For example, novel antigenically distinct 
subtypes of influenza A viruses that are not recognized by neutralizing antibodies and cause 
pandemic outbreaks7. Overuse of antimicrobial drugs and decreased compliance with 
vaccination policies has led to the development of resistant pathogens (e.g., drug-resistance 
Staphylococcus and Campylobacter)8, 9 and re-emergence of diseases that were previously 
under control (e.g., Pertussis and Measles)10, 11. In addition, uncontrolled neglected tropical 
diseases such as Dengue fever and West Nile encephalitis that are endemic in developing 
countries are now emerging in the United States12–14.
In response to these global threats, the National Institute of Allergy and Infectious Diseases 
(NIAID) Systems Biology for Infectious Disease Research Program supports research 
focusing on host-pathogen interactions that are characterized using combined multi-omics 
approaches and dataset integration to “develop and validate predictive models of infectious 
disease initiation, progression, and outcomes”15. Infectious disease research using a systems 
biology approach is imperative to understanding host-pathogen relationships and allows for 
development of new therapies and vaccines16–18. Specifically, proteomics, metabolomics, 
and lipidomics measurements can assist in unraveling host-pathogen relationships. Proteins 
are the major effectors of cellular pathways and represent the dynamic expression of 
information encoded within the genome during infection. Metabolites are intermediates and 
products of cellular pathways and represent the level at which most pharmaceuticals exert 
their effects19. In addition to having key functions in signaling pathways, energy storage and 
the structural integrity of cell membranes, lipids also function in host-pathogen interactions 
and immunomodulation since they act in first line recognition and host cell signaling during 
pathogen docking, invasion and intracellular trafficking20. However, proteomic, 
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metabolomic, and lipidomic characterizations of infectious biological specimens outside of 
appropriate biosafety level (BSL) containment laboratories can take place only subsequent to 
pathogen inactivation.
Non-enveloped viruses such as adenoviruses, noroviruses and bacterial spores are resistant 
to most disinfectants and require alternative methods for inactivation21, 22. Pathogens with 
exposed lipid membranes are more susceptible to disinfectants including detergents and 
other solvents23–25. Organic solvents render many pathogens non-infectious by solubilizing 
and disrupting their lipid membranes or envelopes26–28, and inactivation of pathogens by 
organic solvents has been leveraged for vaccine development29–32, transfusion fluids33–36, 
and sanitation37–39. In systems biology studies of pathogenic bacteria and viruses, it would 
be highly efficient to both inactivate pathogens and extract the molecular components 
needed for proteomic, metabolomic, and lipidomic analyses in a single step. Two of the most 
highly cited publications for lipid-based extraction methods, Folch et al.40 and Dyer et al.41, 
use high ratios of organic solvents to sample (e.g., 4:1), illustrating the broad utility of this 
technique in cell and tissue extraction. Recently, variations of the Folch technique have had 
broader utility in the extraction of metabolites and proteins42–45.
Here, we demonstrate that a modified Folch40 technique using chloroform/methanol for 
simultaneous protein, metabolite, and lipid extraction and subsequent mass spectrometry 
(MS)-based multi-omics analyses also results in concurrent pathogen inactivation. 
Specifically, we investigated if the metabolite, protein and lipid extraction (MPLEx) 
protocol46 could inactivate a diversity of infectious agents with exposed and embedded lipid 
bilayers including three Gram-negative bacteria (Yersinia pestis, Salmonella enterica 
subspecies enterica serovar Typhimurium, and Campylobacter jejuni), Gram-positive 
community-associated methicillin-resistant Staphylococcus aureus (MRSA) isolate 
USA300, Clostridium difficile strain 630 spores and vegetative cells, four RNA viruses 
(West Nile [WNV-New York 1999], MERS-CoV [icMERS], Ebola [Ebola-Zaire delta-
VP30] and Influenza H7N9 [wild-type, A/Anhui/1/13 and mutant A/Anhui/103F-106M]). 
We also tested if MPLEx could inactivate adenovirus type 5, which does not contain an outer 
lipid bilayer.
MPLEx uses chloroform, methanol, and water (8:4:3) to induce a tri-phasic partitioning of 
the sample into metabolite, protein, and lipid fractions. Metabolites are located in the upper 
aqueous layer, whereas lipids are located in the lower organic layer after centrifugation, with 
a protein disc situated between the two phases (Fig. 1). In this study, MPLEx and subsequent 
assessment of pathogen inactivation was performed across multiple laboratories, where each 
laboratory has unique expertise and experience studying the pathogens in question. All 
studies presented in this manuscript were conducted in accordance with appropriate 
biosafety guidelines performed in BSL containment laboratories at the University of 
Wisconsin-Madison, Ohio State University, Washington State University, University of 
North Carolina at Chapel Hill, University of Texas Medical Branch, and Washington 
University School of Medicine, all of which are approved for such use by the Centers for 
Disease Control and Prevention and by the US Department of Agriculture.
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The ability of MPLEx to inactivate pathogens was determined by comparing pathogen 
presence and abundance in either pre-treatment or positive controls vs. MPLEx-treated 
samples. S. Typhimurium, C. jejuni, MRSA, and C. difficile spore inactivation experiments 
(pre-treatment and MPLEx-treated) were replicated 20 times. Y. pestis and viral inactivation 
experiments were replicated 20 times for MPLEx treatment and a single sample was used for 
assessment of viral activity in the pre-treatment or positive control. We describe below the 
basic pathogen inactivation and simultaneous multi-omics extraction protocol. Because 
methods for culturing bacteria and viruses and for establishing infections vary depending on 
the model pathogen, we include those relevant experimental details in the description of 
each study in the Supplemental Material.
MPLEx inactivation protocol
1. In a biosafety cabinet (BSC), remove media from infected cells; immediately 
wash cells with a suitable buffer. The authors recommend a buffer that can be 
used to quench cell metabolism, such as a solution maintained at ~−40°C and 
consisting of 60% methanol and 0.85% ammonium bicarbonate in water47; 
remove rapid quenching solution
2. Add 150 µL of ice-cold 150 mM ammonium bicarbonate solution; scrape cells 
off of plates or wells for cells grown on agar or in well plate format. Collect cells 
and buffer into a 1.5 mL Sorenson microcentrifuge tube (or glass vials); if screw 
cap tops are required (e.g. for BSL-3+ level pathogens) use Fisher Screw Cap 
microcentrifuge tubes (Cat # 3468)
3. Add 600 µL of MPLEx solution (~-40°C chloroform/methanol [CHCl3/MeOH; 
2:1, v/v and a 4-fold excess to sample volume])
4. Vortex for 10 s, leaving the samples on ice for 5 min, and vortex again for 10 s
5. Remove a 100 µl aliquot of mixed solution for inactivation assay
6. Centrifuge the remaining solution at 13,000 g for 10 min
7. Remove top phase to fresh tube, remove bottom phase to second tube leaving 
protein disc behind. Rinse the protein disc with 200 µL methanol and pellet at 
9,000 g for 5 min. Decant the methanol solution and allow pellet to dry in BSC 
for 5 min
8. All tubes are then removed from BSC and BSL containment laboratories after 
appropriate disinfection and either stored at −80°C or dried in vacuo (for safe 
shipping of metabolite and lipid phases) and then stored at −80°C
Some of the bacterial pathogens and all of the viral pathogens were assessed in infection 
studies where infected host cells were treated with MPLEx and inactivation was evaluated 
via inoculation of the resulting cell lysates into fresh cells. For these infection studies, the 
MPLEx-treated cell lysates were diluted to retain host cell viability, as undiluted samples 
can induce toxicity. Some validations of the inactivation procedures were carried out with 
samples that had been dried in the speedvac, rather than the liquid/diluted extract prior to 
drying.
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As depicted in Figure 1 and Figure 2, the MPLEx method for extraction of proteins, 
metabolites and lipids from a single sample for MS-based multi-omics profiling also 
simultaneously inactivates a number of clinically important bacterial and viral pathogens 
with exposed lipid membranes, including Y. pestis CO92, S. Typhimurium, and C. jejuni in 
pure culture and Y. pestis CO92, C. jejuni, WNV, MERS-CoV, Ebola and influenza viruses 
in infection studies. Near complete inactivation (>99%) was observed for pathogens without 
exposed lipid membranes including CA-MRSA, C. difficile 630 spores and vegetative cells 
after ≥ 20 min MPLEx exposure time, and Ad5 (see Supplemental Material and Table S1 for 
details).
In addition, to demonstrating that MPLEx yields biomaterial of sufficient quality for 
subsequent multi-omics analyses, Figure 3 highlights the reproducibility of proteomics, 
metabolomics and lipidomics data from human epithelial lung cells that were infected with 
either wild-type, A/Anhui/1/2013 (H7N9), or A/Anhui/1/2013 (H7N9) possessing two 
mutations in the NS1 gene (L103F and I106M) that reduce virus pathogenicity in mice (A. 
Eisfeld, S. Fan and Y. Kawaoka, unpublished results). To demonstrate the utility of the 
MPLEx protocol for both inactivating pathogens and for obtaining high quality metabolite, 
protein, and lipid fractions for respective omics analyses, we implemented the protocol in a 
systems biology study of influenza infection in a human lung epithelial cell line. The 
MPLEx protocol was implemented to extract proteins, metabolites and lipids from Calu-3 
cells infected with wild-type (AH1) and mutant (FM) influenza viruses, or mock-infected 
controls for each of 6 timepoints; 0, 3, 7, 12, 18 and 24 h, and using 5 biological replicates 
per sample (treatment and timepoint). From this experiment, we quantified 23,688 peptides, 
81 metabolites (50 were identified through matching of experimental mass spectra and 
retention indices to entries in the Agilent Fiehn Metabolomics Retention Time Locked 
Library)48, and 251 and 245 lipids from analyses in negative and positive electrospray mode 
analyses, respectively; therefore as previously reported46 the number of detected analytes 
with MPLEx provides comparable or more identifications compared to other methods. To 
assess reproducibility, we calculated the coefficient of variation (CV) of the 5 biological 
replicates within each of the datatypes (protein, metabolite, and lipid). For proteomics, 
metabolomics, and lipidomics, the maximum CV across features within each set of 
biological replicates was <0.24 (proteomics), < 0.17 (metabolomics), <0.22 (lipidomics data 
collected under negative electrospray ionization (ESI)), and <0.19 (lipidomics data collected 
under positive ESI) (Table S2). Figure 3 shows viral peptides, ribosomal proteins, 
metabolites and lipids significantly increasing in infected samples compared to matched 
mock controls due to infection duration across both viral strains (Table S2). Peptide, 
metabolite, and lipid statistics were performed by comparing data from matched virus and 
mock-infected controls using Analysis of Variance (ANOVA) with a Dunnett multiple test 
correction within time point and for qualitative changes via a G-test with a Bonferroni 
multiple test correction within time point49. Peptides, metabolites, and lipids with a p-value 
less than 0.05 were identified as significantly different (Table S2). The top of Figure 3 
depicts the 123 viral peptides belonging to viral proteins; hemagglutinin (HA), matrix 
protein 1 (M1), neuraminidase (NA), nucleoprotein (NP), NS1, NS2, and RNA polymerase 
complex (PA, PB1, and PB2) significantly increased by G-test (only observed in infected 
samples) as early as 7 h with the number of significant peptides increasing from 7–24 h. 
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Statistical analysis of our proteomic data also found significant quantitative increases in the 
relative abundance of ribosomal subunits 40S and 60S with infection duration across both 
viral strains. During the influenza life cycle, single-stranded viral RNAs migrate to the 
nucleus where they are copied into mRNA by the viral RNA polymerase complex. Invading 
viruses do not harbor functional ribosomes in their virions; therefore, viral mRNAs hijack 
host cell ribosomes and use sophisticated mechanisms50 to enable selective translation of 
viral mRNAs. Free fatty acid metabolites myristic acid (14:0) and oleic acid (18:1) 
significantly increased at 18 h post infection across all 3 viral strains (Fig. 3). Ceramides 
(Cer) containing stearic acid (18:0) and tetracosanoic acid (24:0) significantly increased at 
18 and 24 h in both AH1 and FM and at 12 h in AH1; likewise, Cer containing stearic acid 
(18:0) and nervonic acid (24:1) significantly increased at 18 h in both AH1 and FM and at 
24 h in FM (Fig. 3). It has been previously reported that pathogenic avian influenza viruses, 
such as H7N9, decrease expression of lipid metabolism genes51. A NS1 mutation in the FM 
strain reduces overall pathogenicity; at the early 7 hour time point of infection the wild-type 
AH1 strain shows over a 30% increase in viral peptide compared to the FM mutant (Fig. 3). 
Correspondingly at this 7 h time point ribosome expression is only significantly increased in 
the AH1 virus and at the late 24 hour time point significant ribosomal expression is 
increased by over 40% in the AH1 compared to FM.
Based on these results we believe that MPLEx will benefit and facilitate systems biology 
studies of infectious samples by enabling both pathogen inactivation and multi-omics 
measurements from a single specimen with high success for pathogens with exposed lipid 
membranes. Figures 4 and 5 illustrate the bacterial and viral pathogens from this study that 
contain exposed and embedded lipid membranes; these membranes are denoted with orange 
color. Of the bacterial pathogens characterized in this study, Y. pestis CO92, S. 
Typhimurium, and C. jejuni are Gram-negative bacteria, CA-MRSA is a Gram-positive 
bacterium, and C. difficile 630 is a spore forming Gram-positive bacterium (Fig. 4). The 
exposed walls for Gram-positive bacteria have a higher peptidoglycan (PG) and lower lipid 
content than Gram-negative bacteria. This bacterial classification is based on the Gram 
staining method, which differentiates bacteria by the chemical and physical properties of 
their cell walls; it detects PG, which is present in a thick layer in Gram-positive bacteria52. 
The inner membrane of dormant spores is composed of a bilayer of immobile phospholipids, 
which has similar phospholipid composition to growing bacteria but exhibits low 
permeability to small molecules including water53, 54. This inner membrane surrounds the 
spore core which contains the genome. The basic spore architecture is conserved55–57; 
outside of the inner membrane is a layer of PG, known as the germ cell wall that is encircled 
in a thick layer of a modified form of PG, the cortex, which is essential for the acquisition 
and maintenance of heat resistance. The cortex is surrounded by an outer membrane derived 
from the mother cell that is essential for spore formation but confers no resistance 
properties 58. A proteinaceous coat surrounds the outer membrane. In C. difficile 630 spores, 
the coat is further enclosed within a structure known as the exosporium. The partial 
inactivation results presented for CA-MRSA (where only 2 out of 20 experimental replicates 
still retained a small level of bacterial activity) and C. difficile 630 spores reveals that 
MPLEx can dissolve protective PG layers encircling lipid bilayers and with long enough 
exposure times could lead to complete pathogen inactivation. The level of inactivation of C. 
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difficile 630 spores due to MPLEx treatment exposure time in min was 120 > 20 > 5 (Fig. 
1), in addition in the two replicate experiments of CA-MRSA the experiment with the lower 
initial bacterial concentration (pre-treatment, 4.9 × 108) did show complete inactivation due 
to MPLEx. WNV, MERS-CoV, Ebola, and Influenza H7N9 virus all contain lipid bi-layered 
envelopes (Fig. 5). WNV virions acquire their lipid envelope by budding into the 
endoplasmic reticulum of the host cell; Coronaviruses such as MERS-CoV acquire their 
membranes in the ER-Golgi intermediate compartment (ERGIC) and use normal cellular 
processes to leave the cell; and Ebola and Influenza H7N9 virions acquire their lipid 
envelopes by budding from host plasma membranes often at lipid raft microdomains that are 
enriched in sphingomyelin and cholesterol59–61. Ad5 was the only virus that was not 
completely inactivated by MPLEx; Ad5 is a non-enveloped virus and therefore does not 
contain any lipid membranes (Fig. 5).
In conclusion, we show that MPLEx completely inactivates pathogens with exposed lipid 
membranes, such as enveloped viruses and Gram-negative bacteria, thereby facilitating 
multi-omics measurements from a single specimen in clinically important pathogen studies. 
Pathogens with internal or protected lipid membranes, such as Gram-positive bacteria and 
bacterial spores still show a significant decrease in activity (>99% reduction in the number 
of viable microorganisms after MPLEx treatment) related to both MPLEx solution exposure 
time and pre-treatment pathogen levels. Even Ad5, a virus without a lipid membrane, 
showed >99% decreased activity after MPLEx exposure, presumably since non-enveloped 
viruses can still be susceptible to organic solvent, in particular CHCl3, due to the 
denaturation of proteins that are solvent sensitive28, 62. In summary, we believe our MPLEx 
method for concurrent pathogen inactivation and extraction of samples for multi-omics 
profiling will be broadly applicable to samples containing clinically important bacterial and 
viral pathogens with exposed lipid membranes since molecular characterization of infectious 
samples outside of appropriate biosafety containment can take place only subsequent to 
complete pathogen inactivation. We note that, for biosafety reasons, this protocol should be 
evaluated in each investigator’s laboratory for efficacy in pathogen inactivation, prior to 
implementation and particularly for pathogens that were not evaluated in our study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MPLEx Inactivation of Bacterial Pathogens
(Top, Left) Schematic of our MPLEx extraction method which uses chloroform, methanol, 
and water (8:4:3) to induce simultaneous pathogen inactivation and tri-phasic liquid 
partitioning into metabolite, protein, and lipid fractions. The bargraphs depict the level of 
pathogen inactivation after MPLEx extraction by quantifying the number of Colony Forming 
Units (CFU) in pre-treatment control samples (grey) and MPLEx-treated samples (red) in 
pure cultures of Yersinia pestis strain CO92 (Y. pestis CO92), Salmonella enterica subsp. 
enterica serovar Typhimurium (S. Typhimurium), Campylobacter jejuni (C. jejuni), 
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Methicillin-resistant Staphylococcus aureus USA300 (CA-MRSA), and Clostridium difficile 
strain 630 (C. difficile 630) spores and vegetative cells and in Y. Pestis CO92 and C. jejuni 
infection studies in macrophages and Hela cells, respectively.
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Figure 2. MPLEx Inactivation of Viral Pathogens
The bargraphs depict the level of pathogen inactivation after MPLEx extraction by 
quantifying the number of Focus Forming Units (FFU) or Plaque Forming Units (PFU) in 
pre-treatment control samples (grey) and MPLEx-treated samples (red) in infection studies 
of West Nile (WNV, New York 1999), MERS-CoV (icMERS), Ebola (Ebola-Zaire delta-
VP30) and Avian Influenza (H7N9).
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Figure 3. Reliable multi-omic measurements resulting from MPLEx extraction of influenza 
infected Calu-3 cells
The heatmap depicts significant abundant changes between Calu-3 cells treated with wild-
type (A/Anhui/1/13 [AH1]) and mutant (A/Anhui/103F-106M [FM]) Influenza H7N9 viral 
strains and time-matched (0, 3, 7, 12, 18 and 24 hours) mock-infected controls. Red color, 
significantly increase in virus vs. time matched mock (p-value < 0.05). The viral peptides 
labeled at the top of the heatmap include, hemagglutinin (HA), matrix protein 1 (M1), 
neuraminidase (NA), nucleoprotein (NP), non-structural (NS1), non-structural (NS2) 
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(corresponds to the two unlabeled viral peptides), and polymerase complex proteins (PA, 
PB1, and PB2); fatty acids, FA; Ceramide lipids, Cer.
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Figure 4. The structural layers of Gram-positive and -negative Bacteria and Bacterial Spores
Lipid membranes are denoted with orange color.
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Figure 5. The structure of lipid enveloped viruses; West Nile Virus (WNV), Middle East 
Respiratory Syndrome Coronavirus (MERS-CoV), Ebola, and Avian Influenza Virus
Lipid bilayers are denoted with orange color.
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